| UniProt ID | MAGC2_HUMAN | |
|---|---|---|
| UniProt AC | Q9UBF1 | |
| Protein Name | Melanoma-associated antigen C2 | |
| Gene Name | MAGEC2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 373 | |
| Subcellular Localization | Cytoplasm . Nucleus . Nuclear in germ cells. Cytoplasmic in well-differentiated hepatocellular carcinoma, nuclear in moderately- and poorly-differentiated hepatocellular carcinoma. | |
| Protein Description | Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.. | |
| Protein Sequence | MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSSLILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQKGEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPVILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIKGNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFLWGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASESLSVMSSNVSFSE | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 174 | Phosphorylation | MLMIVIKYKDYFPVI HEEHHHHHCCCHHHH | 9.66 | - | |
| 177 | Phosphorylation | IVIKYKDYFPVILKR HHHHHCCCHHHHHHH | 12.96 | - | |
| 259 | Phosphorylation | VLNAVGVYAGREHFV HHHHHCHHCCCCCEE | 9.45 | 17053785 | |
| 292 | Phosphorylation | EYREVPHSSPPYYEF EEEECCCCCCCCHHH | 38.17 | 26657352 | |
| 293 | Phosphorylation | YREVPHSSPPYYEFL EEECCCCCCCCHHHH | 27.19 | 30266825 | |
| 296 | Phosphorylation | VPHSSPPYYEFLWGP CCCCCCCCHHHHCCC | 21.00 | 30266825 | |
| 297 | Phosphorylation | PHSSPPYYEFLWGPR CCCCCCCHHHHCCCC | 13.13 | 30266825 | |
| 338 | Ubiquitination | SWYKDALKDVEERVQ HHHHHHHHHHHHHHH | 62.54 | - |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of MAGC2_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of MAGC2_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of MAGC2_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| TIF1B_HUMAN | TRIM28 | physical | 20864041 | |
| NSE4A_HUMAN | NSMCE4A | physical | 21364888 | |
| EID3_HUMAN | EID3 | physical | 21364888 | |
| EID2_HUMAN | EID2 | physical | 21364888 | |
| TIF1B_HUMAN | TRIM28 | physical | 21277283 | |
| TIF1B_HUMAN | TRIM28 | physical | 23096706 | |
| ZMY11_HUMAN | ZMYND11 | physical | 24866244 | |
| TIF1B_HUMAN | TRIM28 | physical | 24866244 | |
| P4HA3_HUMAN | P4HA3 | physical | 25416956 | |
| PCGF6_HUMAN | PCGF6 | physical | 25590999 | |
| RN166_HUMAN | RNF166 | physical | 25590999 | |
| TRIM8_HUMAN | TRIM8 | physical | 25590999 | |
| RBX1_HUMAN | RBX1 | physical | 26540345 | |
| CUL1_HUMAN | CUL1 | physical | 26540345 | |
| MAT1_HUMAN | MNAT1 | physical | 25590999 | |
| TRAF4_HUMAN | TRAF4 | physical | 25590999 | |
| UBR3_HUMAN | UBR3 | physical | 25590999 | |
| TIF1B_HUMAN | TRIM28 | physical | 27775077 | |
| STAT3_HUMAN | STAT3 | physical | 27775077 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Tyrosine phosphorylated Par3 regulates epithelial tight junctionassembly promoted by EGFR signaling."; Wang Y., Du D., Fang L., Yang G., Zhang C., Zeng R., Ullrich A.,Lottspeich F., Chen Z.; EMBO J. 25:5058-5070(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-259, AND MASSSPECTROMETRY. | |